It has been demonstrated that only patients with WT KRAS tumors benefit from anti-EGFR monoclonal antibodies treatment in colorectal cancer, while KRAS mutations confer resistance to anti-EGFR therapy [5, 24, 25]. This evidence concerns the gene KRAS and colorectal cancer.